David Dai
Stock Analyst at UBS
(4.01)
# 1,690
Out of 4,581 analysts
96
Total ratings
58.9%
Success rate
11.3%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Rated: Buy | $23 → $31 | $24.15 | +28.36% | 6 | Jul 22, 2026 | |
| ASX: TLX Telix Pharmaceuticals Limited | Maintained: Buy | $31.00 | $14.74 | +110.31% | 14 | Jul 1, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $45 | $35.58 | +26.48% | 2 | Jun 16, 2026 | |
| CGEM Cullinan Therapeutics | Initiated Coverage: Buy | $24 | $17.47 | +37.38% | 7 | Jun 8, 2026 | |
| NBTX Nanobiotix | Maintained: Hold | $30 | $37.82 | -20.68% | 5 | Jun 4, 2026 | |
| KURA Kura Oncology | Maintained: Buy | $15 | $9.31 | +61.12% | 7 | Jun 3, 2026 | |
| BNTX BioNTech SE | Upgraded: Buy | $135 | $92.45 | +46.02% | 1 | May 27, 2026 | |
| ENGN enGene Therapeutics | Maintained: Hold | $9 → $2 | $1.76 | +13.64% | 4 | May 14, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $38 → $37 | $19.63 | +88.49% | 4 | May 13, 2026 | |
| CGON CG Oncology | Maintained: Buy | $90 | $72.62 | +23.93% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $69 → $15 | $15.00 | - | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $0.633 | +136.97% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 → $8 | $2.87 | +178.75% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $4 | $4.70 | -14.89% | 3 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $128 | $106.16 | +20.57% | 2 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $55.81 | -39.07% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $33 | $12.55 | +162.95% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $546 | $490.39 | +11.34% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $134.32 | -16.62% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 | $36.16 | +38.27% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ¥2,690 | ¥6,845 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | ¥53,650 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | ¥3,757 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $6.60 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $3.85 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $2.22 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $19.97 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $8.20 | n/a | 1 | Mar 30, 2022 |
Nurix Therapeutics
Jul 22, 2026
Rated: Buy
Price Target: $23 → $31
Current: $24.15
Upside: +28.36%
Telix Pharmaceuticals Limited
Jul 1, 2026
Maintained: Buy
Price Target: $31.00
Current: $14.74
Upside: +110.31%
Celldex Therapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $45
Current: $35.58
Upside: +26.48%
Cullinan Therapeutics
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $17.47
Upside: +37.38%
Nanobiotix
Jun 4, 2026
Maintained: Hold
Price Target: $30
Current: $37.82
Upside: -20.68%
Kura Oncology
Jun 3, 2026
Maintained: Buy
Price Target: $15
Current: $9.31
Upside: +61.12%
BioNTech SE
May 27, 2026
Upgraded: Buy
Price Target: $135
Current: $92.45
Upside: +46.02%
enGene Therapeutics
May 14, 2026
Maintained: Hold
Price Target: $9 → $2
Current: $1.76
Upside: +13.64%
Syndax Pharmaceuticals
May 13, 2026
Maintained: Buy
Price Target: $38 → $37
Current: $19.63
Upside: +88.49%
CG Oncology
May 8, 2026
Maintained: Buy
Price Target: $90
Current: $72.62
Upside: +23.93%
Apr 15, 2026
Downgraded: Hold
Price Target: $69 → $15
Current: $15.00
Upside: -
Apr 2, 2026
Maintained: Hold
Price Target: $1.5
Current: $0.633
Upside: +136.97%
Mar 18, 2026
Rated: Buy
Price Target: $7 → $8
Current: $2.87
Upside: +178.75%
Mar 5, 2026
Rated: Hold
Price Target: $2 → $4
Current: $4.70
Upside: -14.89%
Mar 3, 2026
Maintained: Buy
Price Target: $90 → $128
Current: $106.16
Upside: +20.57%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $55.81
Upside: -39.07%
Nov 10, 2025
Maintained: Buy
Price Target: $30 → $33
Current: $12.55
Upside: +162.95%
Nov 7, 2025
Maintained: Buy
Price Target: $546
Current: $490.39
Upside: +11.34%
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $134.32
Upside: -16.62%
Oct 24, 2025
Maintained: Buy
Price Target: $50
Current: $36.16
Upside: +38.27%
Apr 2, 2025
Maintained: Hold
Price Target: ¥2,690
Current: ¥6,845
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: ¥53,650
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: ¥3,757
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $6.60
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $3.85
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $40
Current: $2.22
Upside: n/a
May 9, 2022
Maintained: Buy
Price Target: $54
Current: $19.97
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $8.20
Upside: n/a